Hormonal
Dermal white adipose tissue (dWAT) loss and fibrotic transformation due to aging and photodamage reduce adiponectin production, leading to compromised skin health, fine lines, and atrophy.
Prioritize skin health by maintaining healthy dermal fat. Avoid aggressive fat-destroying procedures if possible, as loss of dermal white adipose tissue (dWAT) leads to fibrosis, reduced adiponectin, and faster skin aging. Focus on treatments that support or regenerate small, healthy fat cells rather than just removing volume.
photodamage, and to a lesser extent, aging, cause the adipocyte to myofibroblast transition described previously. This results in fibrotic change to dWAT and sWAT with decreased adipokine production... resulting in fat tissue atrophy, fine lines, and compromised skin health.
Why this rating
Level of Evidence 5 (Therapeutic) editorial/review; relies on cited studies but is not a primary clinical trial itself.
Source
Adipose Tissue, Regeneration, and Skin Health: The Next Regenerative Frontier
Alan D. Widgerow · Aesthetic Surgery Journal Open Forum · 2024
DOI 10.1093/asjof/ojae117
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) cause facial fat atrophy, sagging, and wrinkling ("Ozempic face") by inhibiting adipocyte differentiation and promoting fibrotic transformation of dWAT.Moderate
- Hypertrophic (large) adipocytes promote skin aging by secreting proinflammatory cytokines, downregulating collagen/elastin, and upregulating MMPs, whereas small healthy adipocytes promote skin health via adiponectin.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →